Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more
Ilsung Pharm (003120) - Total Liabilities
Latest total liabilities as of September 2025: ₩13.51 Billion KRW
Based on the latest financial reports, Ilsung Pharm (003120) has total liabilities worth ₩13.51 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ilsung Pharm - Total Liabilities Trend (2013–2024)
This chart illustrates how Ilsung Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ilsung Pharm Competitors by Total Liabilities
The table below lists competitors of Ilsung Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CB Industrial Product Holding
KLSE:7076
|
Malaysia | RM346.84 Million |
|
Kuangli Photoelectric Technology Co Ltd
TW:6431
|
Taiwan | NT$538.70 Million |
|
Dynamic Medical Technologies
TWO:4138
|
Taiwan | NT$1.17 Billion |
|
Element 25 Ltd
AU:E25
|
Australia | AU$7.16 Million |
|
SMC Global Securities Limited
NSE:SMCGLOBAL
|
India | ₹39.82 Billion |
|
Atenor SA
BR:ATEB
|
Belgium | €662.52 Million |
|
Zwack Unicum Likoripari es Kereskedelmi Nyrt.
BUD:ZWACK
|
Hungary | Ft9.95 Billion |
|
Ispire Technology Inc. Common Stock
NASDAQ:ISPR
|
USA | $92.06 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Ilsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ilsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ilsung Pharm (2013–2024)
The table below shows the annual total liabilities of Ilsung Pharm from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩11.75 Billion | -67.77% |
| 2023-12-31 | ₩36.44 Billion | -25.42% |
| 2022-12-31 | ₩48.85 Billion | +91.78% |
| 2021-12-31 | ₩25.47 Billion | +7.26% |
| 2020-12-31 | ₩23.75 Billion | -1.16% |
| 2019-12-31 | ₩24.03 Billion | +4.79% |
| 2018-12-31 | ₩22.93 Billion | -6.93% |
| 2017-12-31 | ₩24.64 Billion | +33.88% |
| 2016-12-31 | ₩18.40 Billion | -62.20% |
| 2015-12-31 | ₩48.69 Billion | -2.02% |
| 2014-12-31 | ₩49.69 Billion | -0.45% |
| 2013-12-31 | ₩49.92 Billion | -- |